Expand ZURA Menu
ZURA MENU

ZURA Latest Press Releases

-- June 29, 2026 --

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program Business Wire 7:30 AM

-- May 14, 2026 --

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire 7:30 AM

-- May 13, 2026 --

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer Business Wire 7:30 AM

-- May 7, 2026 --

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates Business Wire 7:30 AM

-- May 4, 2026 --

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire 4:05 PM

-- March 19, 2026 --

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates Business Wire 4:05 PM

-- March 5, 2026 --

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress Business Wire 6:30 AM

-- March 2, 2026 --

Zura Bio to Participate in Upcoming Investor Conferences Business Wire 6:30 AM

-- February 27, 2026 --

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares Business Wire 6:30 AM

-- February 25, 2026 --

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants Business Wire 6:30 AM

-- February 24, 2026 --

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants Business Wire 4:01 PM

-- February 23, 2026 --

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors Business Wire 6:30 AM

-- February 4, 2026 --

Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit Business Wire 6:30 AM
Market Data Delayed 15 Minutes